osimertinib
astrazeneca
['nsclc', 'lcsm,(-blcsm)', 'sclc', 'osimertinib']
adjuvant osimertinib provides os benefit in egfr+ stage ib-iiia nsclc #asco23 #lcsm
SVP, Content @MJHLifeSciences. Focused on creating innovative, expert-driven content @OncLive @MedEconomics @AJMC_Journal @Pharmacy_Times @MDMagazine plus more